Annual EBITDA
-$165.43 M
+$44.12 M+21.06%
31 December 2023
Summary:
Centessa Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$165.43 million, with the most recent change of +$44.12 million (+21.06%) on 31 December 2023. During the last 3 years, it has fallen by -$155.14 million (-1508.41%). CNTA annual EBITDA is now -3250.72% below its all-time high of -$4.94 million, reached on 31 December 2019.CNTA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$39.16 M
+$1.19 M+2.94%
30 September 2024
Summary:
Centessa Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$39.16 million, with the most recent change of +$1.19 million (+2.94%) on 30 September 2024. Over the past year, it has dropped by -$470.00 thousand (-1.21%). CNTA quarterly EBITDA is now -186.58% below its all-time high of $45.23 million, reached on 01 December 2020.CNTA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$147.19 M
-$470.00 K-0.32%
30 September 2024
Summary:
Centessa Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently -$147.19 million, with the most recent change of -$470.00 thousand (-0.32%) on 30 September 2024. Over the past year, it has increased by +$26.96 million (+15.48%). CNTA TTM EBITDA is now -275.29% below its all-time high of $83.97 million, reached on 31 March 2021.CNTA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CNTA EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +21.1% | -1.2% | +15.5% |
| 3 y3 years | -1508.4% | +2.5% | -6336.8% |
| 5 y5 years | - | - | - |
CNTA EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -1508.4% | +21.1% | -19.1% | +37.8% | -6336.8% | +29.8% |
| 5 y | 5 years | -3250.7% | +21.1% | -186.6% | +37.8% | -275.3% | +29.8% |
| alltime | all time | -3250.7% | +21.1% | -186.6% | +37.8% | -275.3% | +29.8% |
Centessa Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$39.16 M(-2.9%) | -$147.19 M(+0.3%) |
| June 2024 | - | -$40.35 M(+16.0%) | -$146.72 M(-3.9%) |
| Mar 2024 | - | -$34.80 M(+5.8%) | -$152.62 M(-7.7%) |
| Dec 2023 | -$165.43 M(-21.1%) | -$32.88 M(-15.0%) | -$165.43 M(-5.0%) |
| Sept 2023 | - | -$38.70 M(-16.3%) | -$174.15 M(-7.1%) |
| June 2023 | - | -$46.25 M(-2.8%) | -$187.51 M(-8.2%) |
| Mar 2023 | - | -$47.60 M(+14.4%) | -$204.26 M(-2.5%) |
| Dec 2022 | -$209.55 M | -$41.60 M(-20.1%) | -$209.54 M(+24.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2022 | - | -$52.06 M(-17.4%) | -$167.95 M(+7.6%) |
| June 2022 | - | -$63.00 M(+19.1%) | -$156.04 M(+16.0%) |
| Mar 2022 | - | -$52.89 M(+31.7%) | -$134.50 M(-5799.0%) |
| Sept 2021 | - | -$40.16 M(-3.1%) | $2.36 M(-94.4%) |
| June 2021 | - | -$41.45 M(-207.0%) | $42.52 M(-49.4%) |
| Mar 2021 | - | $38.73 M(-14.4%) | $83.97 M(+85.6%) |
| Dec 2020 | -$10.29 M(+108.3%) | - | - |
| Dec 2020 | - | $45.23 M | $45.23 M |
| Dec 2019 | -$4.94 M | - | - |
FAQ
- What is Centessa Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Centessa Pharmaceuticals?
- What is Centessa Pharmaceuticals annual EBITDA year-on-year change?
- What is Centessa Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Centessa Pharmaceuticals?
- What is Centessa Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Centessa Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Centessa Pharmaceuticals?
- What is Centessa Pharmaceuticals TTM EBITDA year-on-year change?
What is Centessa Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of CNTA is -$165.43 M
What is the all time high annual EBITDA for Centessa Pharmaceuticals?
Centessa Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is -$4.94 M
What is Centessa Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, CNTA annual earnings before interest, taxes, depreciation & amortization has changed by +$44.12 M (+21.06%)
What is Centessa Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of CNTA is -$39.16 M
What is the all time high quarterly EBITDA for Centessa Pharmaceuticals?
Centessa Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $45.23 M
What is Centessa Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, CNTA quarterly earnings before interest, taxes, depreciation & amortization has changed by -$470.00 K (-1.21%)
What is Centessa Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of CNTA is -$147.19 M
What is the all time high TTM EBITDA for Centessa Pharmaceuticals?
Centessa Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $83.97 M
What is Centessa Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, CNTA TTM earnings before interest, taxes, depreciation & amortization has changed by +$26.96 M (+15.48%)